Safety of Live Attenuated Influenza Vaccine (LAIV) in Children 2-18 Years, Vaccine Adverse Event Reporting System (VAERS), 2005-2010

被引：0
|
作者：
Haber, Penina [1 ]
Moro, Pedro L. [1 ]
Vellozzi, Claudia [1 ]
Lewis, Paige [1 ]
Yue, Xin [1 ]
Broder, Karen [1 ]
机构：
[1] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
728
引用
收藏
页码：S316 / S316
页数：1
相关论文
共 50 条
  • [31] Comparative safety of two recombinant hepatitis B vaccines in children: Data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
    Niu, MT
    Rhodes, P
    Salive, M
    Lively, T
    Davis, DM
    Black, S
    Shinefield, H
    Chen, RT
    Ellenberg, SS
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (06) : 503 - 510
  • [32] Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015
    Miller, Elaine R.
    Lewis, Paige
    Shimabukuro, Tom T.
    Su, John
    Moro, Pedro
    Woo, Emily Jane
    Jankosky, Christopher
    Cano, Maria
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1963 - 1969
  • [33] Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS)
    Russell, M
    Pool, V
    Kelso, JA
    Tomazic-Jezic, VJ
    VACCINE, 2004, 23 (05) : 664 - 667
  • [34] Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system
    Woo, Emily Jane
    Moro, Pedro L.
    VACCINE, 2021, 39 (13) : 1812 - 1817
  • [35] Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System
    Woo, Emily Jane
    Moro, Pedro L.
    Cano, Maria
    Jankosky, Christopher
    VACCINE, 2017, 35 (42) : 5618 - 5621
  • [36] The safety of live attenuated influenza vaccine in children and adolescents 2 through 17years of age: A Vaccine Safety Datalink study
    Daley, Matthew F.
    Clarke, Christina L.
    Glanz, Jason M.
    Xu, Stanley
    Hambidge, Simon J.
    Donahue, James G.
    Nordin, James D.
    Klein, Nicola P.
    Jacobsen, Steven J.
    Naleway, Allison L.
    Jackson, Michael L.
    Lee, Grace
    Duffy, Jonathan
    Weintraub, Eric
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (01) : 59 - 68
  • [37] COST-EFFECTIVENESS OF VACCINATING CHILDREN AGED 2-17 YEARS WITH INTRANASAL LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IN GERMANY
    Damm, O.
    Rose, M. A.
    Greiner, W.
    Knuf, M.
    Wahn, U.
    Krueger, H.
    Wutzler, P.
    Schaberg, T.
    Ruf, B.
    Liese, J. G.
    Eichner, M.
    VALUE IN HEALTH, 2011, 14 (07) : A280 - A280
  • [38] Data Mining for Prospective Early Detection of Safety Signals in the Vaccine Adverse Event Reporting System (VAERS): A Case Study of Febrile Seizures after a 2010–2011 Seasonal Influenza Virus Vaccine
    David Martin
    David Menschik
    Marthe Bryant-Genevier
    Robert Ball
    Drug Safety, 2013, 36 : 547 - 556
  • [39] Association Between Influenza Vaccination and Development of Guillain-Barre Syndrome in Adults: A Vaccine Safety Datalink (VSD) and Vaccine Adverse Event Reporting System (VAERS) Study
    Gomez, Francisco
    El-Ghanem, Mohammad
    Nasar, Abu
    Souayah, Nizar
    NEUROLOGY, 2016, 86
  • [40] Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children
    Bracco Neto, Humberto
    Farhat, Calil K.
    Tregnaghi, Miguel Wenceslao
    Madhi, Shabir A.
    Razmpour, Ahmad
    Palladino, Giuseppe
    Small, Margaret G.
    Gruber, William C.
    Forrest, Bruce D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (05) : 365 - 371
12345